Actinium Pharmaceuticals Inc (NYSE AMERICAN: ATNM), clinical-stage biopharmaceutical company, announced yesterday that it has named Niva Almaula, PhD as chief business officer, effective immediately.

Dr Almaula joins Actinium with significant experience in the targeted radiotherapy field, having most recently worked as head, Business Development at Advanced Accelerator Applications Inc. She comes to Actinium with twenty years of biopharmaceutical industry experience. She joins Actinium from Advanced Accelerator Applications Inc. Dr Almaula joined AAAP in May 2015 where she was head, Business Development responsible for leading the global business development activities to strategically build AAAP's oncology portfolio. During her time at AAAP, Dr Almaula executed three exclusive licenses that expanded the company's therapeutic and diagnostic pipeline and represented AAAP to potential partners and collaborators. Prior to AAAP, she was founder and partner of Octane BioVentures, where she provided business development and strategy consulting services to early stage life science companies. Previously, she worked in alliance management and business development at Dr Reddy's Labs, Biologics and Nycomed (now Takeda). Dr Almaula also worked for Bio-IB LLC. She began her career at Mehta Partners LLC in biotechnology equity research.

Sandesh Seth, Actinium's chairman and CEO, said, 'I am delighted to welcome Dr Almaula to the Actinium team and look forward to working with her to execute on multiple initiatives focused on deriving maximum value from our wide array of assets. Amidst a backdrop of growing interest for targeted radiotherapy, we have created an exciting business that encompasses our highly differentiated clinical stage ARC's, AWE technology platform, a leadership position in the utilisation of actinium-225, a broad intellectual property portfolio and robust supply chain capabilities. Further, we are unique as having the only multi-target, multi-indication clinical stage pipeline in the field of targeted conditioning, which represents an exciting potential strategic business unit and enables optionality with our ARC combination and therapies, next generation ARC's and AWE platform. Considering Dr Almaula's deep technical and domain expertise in the field of targeted radiotherapies gained during her time at Advanced Accelerator Applications Inc. and proven business development skills, I am confident in her ability to leverage Actinium's ARC and AWE technologies to help us execute against our strategic vision.'